Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

That includes Novo Nordisk's weight loss drug Wegovy and Eli Lilly's obesity treatment Zepbound, which have hefty list prices of roughly $1,000 per month before insurance or savings cards.

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Zepbound is approved for weight loss and management, while Mounjaro is approved for the treatment of Type 2 diabetes. — Comorbidities. Mounjaro is approved for those with Type 2 diabetes.

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...